Imaging VS Postmortem Receptor Studies: What You See is What You Get?

  • Lyn Pilowsky
Part of the Neurobiological Foundation of Aberrant Behaviors book series (NFAB, volume 4)

Abstract

Postmortem research historically provided the technical and evidential basis for in vivo receptor imaging. In vitro mapping of receptor distribution and density is an essential first step for novel tracer development in order to image brain receptors in a living human subject. The chapter reviews the technical distinctions between receptor estimation postmortem and in vivo. The advantages and disadvantages of each approach are also discussed with respect to psychiatric disorder in particular. The neuropharmacology of schizophrenia has been most studied with neuroreceptor imaging and is used as an instructive example of the contribution of both methodologies to understanding the role of dopamine in the disorder. These data include simple studies estimating dopamine D2 receptors in schizophrenia, dynamic in vivo challenges of the dopamine system, and examining the links between dopamine D2 receptor occupancy by antipsychotic drugs and their toxic and therapeutic effects. These studies reveal the necessity of bridging the gap between ante- and postmortem research in schizophrenia and other disorders.

Keywords

Antipsychotic Drug Receptor Occupancy Striatal Dopamine Atypical Antipsychotic Drug Bioi Psychiatry 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Benes FM. (2001) The study of neural circuitry in schizophrenia using postmortem and brain imaging approaches. Biol Psychiatry 2001; 49: 3S.Google Scholar
  2. Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ, Gacinovic S, Kerwin RW, Pilowsky LS. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine-a 1231 epidepride single photon emission tomography (SPET) study. Psychopharmacology 2000; 150: 132–140.PubMedCrossRefGoogle Scholar
  3. Clow A, Theodoru A, Jenner P, et al. Changes in rat striatal dopamine turnover and receptor activity during one year’s neuroleptic administration. Eur J Pharmacology 1980; 63: 135144.Google Scholar
  4. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481–483.PubMedCrossRefGoogle Scholar
  5. Delforge J, Bottlaender M, Pappata S, Loc’h C, Syrota A. Absolute quantification by positron emission tomography of the endogenous ligand. J Cer Blood Flow Metab 2001; 21: 613–630.CrossRefGoogle Scholar
  6. Ichise M, Meyer J, Yonekura Y. An introduction to PET and SPECT neuroreceptor quantification models. J Nuc Med 2001; 42: 755–763.Google Scholar
  7. Innis RB, Malison RT, Al-Tikriti M, Hoffer PB, Sybirska EH, Seibyl JP, Zoghbi SS. Amphetamine-Stimulated Dopamine Release competes In Vivo for (I)IBZM Binding to the D2 Receptor in Nonhuman Primates. Synapse 1992; 10: 177–184.PubMedCrossRefGoogle Scholar
  8. Janowsky A, Neve KA, Kinsie MJ, Taylor B, de Paulis T, Belknap J. Extrastriatal dopamine D2 receptors: distribution, pharmacological characterisation and region specific regulation by clozapine. J Pharm Exp Ther 1992; 261: 1282–1290.Google Scholar
  9. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156: 286–93.PubMedGoogle Scholar
  10. Kapur S, Barlow K, Vanderspek SC, Javanmard M, Nobrega JN. Drug induced receptor occupancy: substantial differences in measurements made in vivo vs ex vivo. Psychophannacology 2001; published online DOI 10.1007/x002130100790.Google Scholar
  11. Kessler RM, Mason NS, Votaw JR, De Paulis TD, Clanton JA., Sib Ansari M, Schmidt DE, Manning RG, Bell RL. Visualisation of extrastriatal dopamine D2 receptors in the human brain. Eur J Pharmacol 1992; 223: 105–107.PubMedCrossRefGoogle Scholar
  12. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D’Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 1996; 93: 9235–40.PubMedCrossRefGoogle Scholar
  13. Lamelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques-a criticial review, J Cer Blood Flow Metab 2000; 20: 423–451.Google Scholar
  14. Lee T, Seeman P (1980) Elevation of Brain Neuroleptic/Dopamine receptors in Schizophrenia, Am J Psychiary 1980; 137: 191–197.Google Scholar
  15. Mackay AVP, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I, Snyder SH. Increased brain dopamine and dopamine receptors in schizophrenia Arch Gen Psychiat 1982; 39: 991–997.Google Scholar
  16. Manji HK, Lenox RH. Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 2000; 48: 518–30.PubMedCrossRefGoogle Scholar
  17. Mann JJ. Postmortem versus in vivo imaging: comparison of anatomical and temporal scale. Biol Psychiatry 2001; 49: 2S.Google Scholar
  18. Martinot J-L, Peron-Magnan P, Huret J-D et al. Striatal D2 dopaminergic receptors assessed with positron emission tomography and 76Br Bromospiperone in untreated schizophrenic patients. Am J Psychiatry 1990; 147: 44–50.PubMedGoogle Scholar
  19. Meltzer HY, Park S, Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc Natl Acad Sci USA 1999; 96: 13591–3.PubMedCrossRefGoogle Scholar
  20. Moore H, West AR, Grace AA. The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia Biol Psychiatry 1999; 46: 40–55.Google Scholar
  21. Nordstrom AL, Farde L, Eriksson L, Halldin C. No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. Psych Res 1995; 61: 67–83.CrossRefGoogle Scholar
  22. Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 5HT2 and D2 dopamine receptor occupancy by risperidone in the living human brain. Psychopharmacology 1993; 110: 265272.Google Scholar
  23. Peroutka SJ, Snyder SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic and histaminergic receptors to clinical potency. Am J Psychiatry 1980; 137: 1518–1522.PubMedGoogle Scholar
  24. Pilowsky LS, Costa DC, Ell PJ, Murray R, Verhoeff N, Kerwin RW. Clozapine, single photon emission tomography and the D2 dopamine receptor blockade hypothesis of schizophrenia Lancet 1992; 340: 199–202.Google Scholar
  25. Pilowsky LS, Costa DC, Ell PJ, Verhoeff NPLG, Murray RM, Kerwin RW. D2 dopamine receptor binding in the basal ganglia of antipsychotic free schizophrenic patients-a 1231 IBZM single photon emission tomography (SPET) study. Br J Psychiatry 1994; 164: 16–26.Google Scholar
  26. Pilowsky LS, Costa DC, Ell PJ, Murray R, Verhoeff N, Kerwin RW (1993) Antipsychotic medication, D2 dopamine receptor blockade and clinical response-a 1231 IBZM SPET (single photon emission tomography) study. Psychol Med 1993; 23: 791–799.CrossRefGoogle Scholar
  27. Pilowsky LS, Mulligan R, Acton P, Costa D, Ell P, Kerwin RW. Limbic selectivity of clozapine. Lancet 1997; 350: 490–491.PubMedCrossRefGoogle Scholar
  28. Seeman P, Niznik HB, Guan HC. Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride. Arch Gen Psychiatry 1990; 47: 1170–1172.PubMedCrossRefGoogle Scholar
  29. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson AA, Christensen BK, Seeman P. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000; 152: 174–80.CrossRefGoogle Scholar
  30. Strange PG. Antipsychotic Drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects, Pharmacol Rev 2001; 53: 119–133.PubMedGoogle Scholar
  31. Talvik M, Nordstrom AL, Nyberg S, Olsson H, Halldin C, Farde L. No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(I1)C]FLB 457. Am J Psychiatry 2001; 158: 926–30.PubMedGoogle Scholar
  32. Travis MJ, Busatto GF, Pilowsky LS, Mulligan R, Acton PD, Gacinovic S, Mertens J, Terriere D, Costa DC, Ell PJ, Kerwin RW. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5HT2A ligand 123I-5-I-R-91150. Br J Psychiatry 1998; 173: 236–41.PubMedCrossRefGoogle Scholar
  33. Wong DF, Wagner HN, Dannals RF, et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 1984; 226: 1393–1396.PubMedCrossRefGoogle Scholar
  34. Wong DF, Wagner Jr. HN, Tune LE et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234: 1558–1563.PubMedCrossRefGoogle Scholar
  35. Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loch C, Maziere B, Paillere-Martinot ML. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 2001; 21: 207–14.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Lyn Pilowsky

There are no affiliations available

Personalised recommendations